text: <unk> , a myeloproliferative disorder, is characterized by the proliferation of megakaryocytes in the bone marrow, disrupted cytokine production, and reactive fibrosis resulting in bone marrow failure. The fibrosed and scarred bone marrow produces fewer and fewer normal functioning blood cells leading to pancytopenia and extramedullary hematopoiesis (EMH). It can mainly be associated with somatic mutation of the myeloproliferative leukemia virus (MPL) oncogene, the calreticulin (CALR) gene, or Janus kinase 2 (JAK2) gene but other genes can also be involved and it can also result in the setting of another primary insult. Associated conditions include malignancies, hematologic disorders, infections, autoimmune diseases, and endocrine disorders. Hepatomegaly, splenomegaly, and lymphadenopathy are the positive findings on gross pathology. On microscopic pathology,<unk>  is characterized by low RBC count, leukopenia - leukocytosis, basophilia, erythroblastosis, thrombocytopenia - thrombocytosis, micromegakaryocytes, splenic pulp changes, and abnormalities of platelets.
option_0: Myelofibrosis pathophysiology
option_1: Myelodysplastic syndrome pathophysiology
option_2: Myelofibrosis risk factors
option_3: Polycythemia pathophysiology
option_4: Acute myeloid leukemia pathophysiology
option_5: Myelofibrosis causes
option_6: Chronic myelogenous leukemia pathophysiology
option_7: POEMS syndrome pathophysiology